Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of 5-grass Mix SLIT-drops in Adults With Grass Pollen-induced Rhinoconjunctivitis

Next Previous
X
Search
Trial Profile

A Randomised, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of 5-grass Mix SLIT-drops in Adults With Grass Pollen-induced Rhinoconjunctivitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
  • Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms Rhapsody; SU-G-01
  • Sponsors ALK-Abello

    • Most Recent Events

    • 29 Aug 2024 This trial has been Completed in Lithunia, According to European Clinical Trials Database record
    • 05 Feb 2024 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2023 This trial has been completed in Czechia (End Date: 26 Sep 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top